Motivated by a growing understanding that PAX3‐FOXO1 fusion proteins interact with diverse epigenetic complexes, including BRD4 [11, 12] and CHD4 [13], we hypothesized that BMI1 would contribute to ARMS aggression and that inhibiting this protein could potentially confer therapeutic benefit. The gene discussed is BMI1; the disease is alveolar rhabdomyosarcoma.